The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: A meta-analysis

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 9, 2009, Pages 596-603

  Ma, J ^a   Yang, W ^b   Fang, N ^b   Zhu, W ^a   Wei, M ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Intensive glycemic control; Meta analysis; Randomized controlled trial; Type 2 diabetes mellitus; Vascular complications

Indexed keywords

ANTIDIABETIC AGENT;

ARTICLE; DIABETIC ANGIOPATHY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70350567207     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.07.004     Document Type: Article

References (28)

1. Klein R., Klein B.E., and Moss S.E. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 124 (1996) 90-96
2. Gaster B., and Hirsch I.B. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 158 (1998) 134-140
3. Gu K., Cowie C.C., and Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA 281 (1999) 1291-1297
4. Balducci S., Zanuso S., Massarini M., Corigliano G., Nicolucci A., Missori S., et al. The Italian diabetes and exercise study (IDES): design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in people with type 2 diabetes and the metabolic syndrome. Nutr Metab Cardiovasc Dis 18 (2008) 585-595 10.1016/j.numecd.2007.07.006
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853 10.1016/S0140-6736(98)07019-6
6. Shichiri M., Kishikawa H., Ohkubo Y., and Wake N. Long-term results of the kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 Suppl. 2 (2000) B21-B29
7. Goldstein D.E., Little R.R., Lorenz R.A., Malone J.I., Nathan D., and Peterson C.M. Tests of glycemia in diabetes. Diabetes Care 18 (1995) 896-909
8. American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care 31 (2008) S12-S54 10.2337/dc08-S012
9. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes (2005), International Diabetes Federation, Brussels
10. Rydén L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European society of cardiology (esc) and of the European association for the study of diabetes (EASD). Eur Heart J 28 (2007) 88-136 10.1093/eurheartj/ehl260
11. Ceriello A., Colagiuri S., Gerich J., and Tuomilehto J. Guideline development group. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis 18 (2008) S17-S33 10.1016/j.numecd.2008.01.012
12. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
13. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
14. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009) 129-139
15. Higgins J.P.T., and Green S. Cochrane handbook for systematic reviews of interventions version 5.0.0. [update February 2008] (2008), The Cochrane Collaboration
16. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analysis. BMJ 327 (2003) 557-560 10.1136/bmj.327.7414.557
17. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macrovascular events): a randomized controlled trial. Lancet 366 (2005) 1279-1289 10.1016/S0140-6736(05)67528-9
18. Abraira C., Colwell J., Nuttall F., Sawin C.T., Henderson W., Comstock J.P., et al. Cardiovascular events and correlates in the veterans affairs diabetes feasibility trial. Veterans affairs cooperative study on glycemic control and complications in type II diabetes. Arch Intern Med 157 (1997) 181-188
19. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
20. Standl E., Balletshofer B., Dahl B., Weichenhain B., Stiegler H., Hörmann A., et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich general practitioner project. Diabetologia 39 (1996) 1540-1545 10.1007/s001250050612
21. Lehto S., Rönnemaa T., Haffner S.M., Pyörälä K., Kallio V., and Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middleaged patients with NIDDM. Diabetes 46 (1997) 1354-1359
22. Moss S.E., Klein R., and Klein B.E. The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin epidemiologic study of diabetic retinopathy. Diabetes Care 22 (1999) 951-959
23. Roselli della Rovere G., Lapolla A., Sartore G., Rossetti C., Zambon S., Minicuci N., et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis 13 (2003) 46-51 10.1016/S0939-4753(03)80167-9
24. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 (2004) 421-431
25. Stettler C., Allemann S., Jüni P., Cull C.A., Holman R.R., Egger M., et al. Glycemic control and macrovascular disease in type 1 and type 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 152 (2006) 27-38 10.1016/j.ahj.2005.09.015
26. Qaseem A., Vijan S., Snow V., Cross T., Weiss K.B., Owens D.K., et al. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin a1c targets. A guidance statement from the American college of physicians. Ann Intern Med 147 (2007) 417-422
27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
28. Thomaseth K., Pacini G., Morelli P., and Nosadini R. Importance of glycemic control on the course of glomerular filtration rate in type 2 diabetes with hypertension and microalbuminuria under tight blood pressure control. Nutr Metab Cardiovasc Dis 18 (2008) 632-638 10.1016/j.numecd.2007.05.006